Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study.

Objective To evaluate the relative bioavailability of a new formulation containing 5 mg mosapride and 10 mg rabeprazole (T) and compare it with the branded formulations of both drugs co-administered in separate tablets (R) to meet the regulatory requirements of bioequivalence in Argentina. Methods: A randomized-sequence open-label, two-period crossover study was conducted on 24 healthy Caucasian volunteers in a fasting state. A single oral dose of either T or R formulations was followed by a 7-day washout period, Blood samples for mosapride were collected before administration (baseline) and at 0.5, 1, 1.5, 2. 2,5, 3, 4, 6, 8, 12, 18, and 24 h after administration. Samples for rabeprazole were taken baseline and at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8 and 10 h after dosing. Mosapride and rabeprazole concentrations were determined using a validated LC-MS/MS method. Adverse events were monitored based on clinical parameters and volunteer reports. Results: The geometric means (90% CI) C(max) for mosapride in T and R were 23.13 (20.05-39.45) and 23.09 (21.69-32.37) ng/mL, the AUC(0-t) were 70.80 (66.23-102,37) and 70.81 (66.35-93,26) ng h/mL and the AUC(0-infinity) were 74.05 (69.29-106.11) and 74.98 (70.43-97.77) ng filmL. For rabeprazole land R the C(max) were 197.42 (186.12-239.91) and 195.50 (186.08-250.07) ng/mL, the AUC(0-t) were 294.90 (275.13-374.15) (74.15) and 296.96 (280.11-387.89) ng h/mL and the AUC(0-infinity) were 301.12 (280.78-380.82) and 304.07 (286.60-394.21), respectively. No differences were detected between the formulations. The T/R ratios (90% CI) for C(max) AUC(0-t) and AUC(0-infinity), were 100.17% (82.35-121,84), 99.99% (87.58-114.16) and 98.77% (87.02-112.11) for mosapride, and 100.99% (85.14-119.77), 99.31% (84.74-116.38) and 99.03% (85.07-115.28) for rabeprazole. No subject complained of adverse events. Conclusions: In this single-dose study, the mosapride/rabeprazole tablets (test formulation) met the criterion for bioeguivalence with the reference formulations. Study limitations include single-dose, open-label design, and a small sample of healthy volunteers.